**Nerve Graft with Radical Prostatectomy**

**Effective:** September 1, 2023

**Next Review:** July 2024  
**Last Review:** July 2023

---

**IMPORTANT REMINDER**

Medical Policies are developed to provide guidance for members and providers regarding coverage in accordance with contract terms. Benefit determinations are based in all cases on the applicable contract language. To the extent there may be any conflict between the Medical Policy and contract language, the contract language takes precedence.

PLEASE NOTE: Contracts exclude from coverage, among other things, services or procedures that are considered investigational or cosmetic. Providers may bill members for services or procedures that are considered investigational or cosmetic. Providers are encouraged to inform members before rendering such services that the members are likely to be financially responsible for the cost of these services.

---

**DESCRIPTION**

Nerve grafting is performed to replace cavernous nerves that have been resected during radical prostatectomy for prostate cancer.

---

**MEDICAL POLICY CRITERIA**

Unilateral or bilateral nerve graft is considered **not medically necessary** in patients who have undergone resection of one or both neurovascular bundles as part of a radical prostatectomy.

**NOTE:** A summary of the supporting rationale for the policy criteria is at the end of the policy.

---

**CROSS REFERENCES**

None

---

**BACKGROUND**

Patients with prostate cancer may undergo treatment with prostatectomy or prostate radiation therapy. Nerve grafting is performed to replace cavernous nerves that have been resected...
during radical prostatectomy in individuals with prostate cancer. The intent of this nerve
grafting is to treat the erectile dysfunction that is a common problem when nerve sparing
surgical techniques are unsuccessful or cannot be accomplished due to the location or extent
of the tumor. The sural nerve, the most common donor nerve, is considered expendable and
has been used extensively in other nerve grafting procedures, such as brachial plexus and
peripheral nerve injuries. A portion of the sural nerve is harvested from one leg and then
anastomosed to the divided ends of the cavernous nerve. Other nerves, such as the
genitofemoral nerve, have also been used. Grafting may be unilateral or bilateral. Several
studies have reported racial disparities among individuals with low-risk prostate cancer.[1]
African American individuals enrolled in active surveillance programs have been shown to
have a higher risk of disease progression than individuals who identified as white. For African
American individuals in the low-to-intermediate risk categories, there have been reports of
increased risk of biochemical recurrence after treatment. While reasons for clinical disparities
in this population are still being investigated, studies suggest that disparities in prostate cancer
health outcomes can be minimized when health care access is equal.

REGULATORY STATUS

A nerve graft in association with radical prostatectomy is a surgical procedure and as such is
not subject to regulation by the U.S. Food and Drug Administration (FDA).

EVIDENCE SUMMARY

In order to isolate the specific therapeutic effects of sural nerve grafting and individual patient
differences (clinical and demographic, known and unknown), well-designed randomized
controlled trials (RCTs) that compare groups of patients undergoing radical prostatectomy with
and without sural nerve grafting are necessary. Primary outcomes include differences in
proportion of individuals experiencing improvement in sexual dysfunction (as measured by a
standardized assessment tool), and rates of adverse effects. Although informative, evidence
from observational studies describing experiences of sural nerve grafted individuals is of
limited utility in establishing causal relationships; therefore, the focus of the literature appraisal
below is on RCTs investigating sural nerve grafting for erectile dysfunction.

SYSTEMATIC REVIEWS

There were no systematic reviews identified.

RANDOMIZED CONTROLLED TRIAL

A sole RCT by Davis (2009) has been identified which compared unilateral nerve sparing
radical prostatectomy with, versus without, unilateral sural nerve grafting.[2] The trial was
discontinued before full enrollment was achieved because there was adequate data at interim
analysis of 107 individuals with two-year follow-up to determine that nerve grafting was not
beneficial. At two-year follow-up, there was no significant difference in erectile or urinary
function, quality of life, or time to potency between the two groups. The results of this trial
warrant cautious interpretation. Individuals were not blinded to their treatment group
assignment; thus, the possibility of treatment bias cannot be ruled out.

NONRANDOMIZED STUDIES

Trindade (2017) evaluated the long-term treatment of erectile dysfunction using penile
reinnervation after a radical prostatectomy.[3] A group of 10 individuals underwent penile
reinnervation by bridging the femoral nerve to the dorsal nerve of the penis and the inner part of the corpus cavernosum with sural nerve grafts. Six out of 10 individuals were able to achieve full penetration within an average of 13 months post reinnervation surgery. The authors noted that individuals previously submitted to radiotherapy had a slower return of erectile function.

A cohort study by Kung (2015) included 38 individuals who underwent nerve grafting after radical prostatectomy and a random sample of 53 control individuals who had open prostatectomy without nerve grafting. Control individuals had unilateral or bilateral nerve sparing prostatectomy, or non-nerve sparing prostatectomy. Complete urinary incontinence, no erectile capacity at baseline, and follow-up data less than 12 months were study exclusion criteria. Unilateral nerve grafting (n=29) and unilateral nerve sparing (n=10) individuals did not differ significantly for various outcomes, including urinary continence, erections sufficient for sex, spontaneous erections, and use of erectile dysfunction medications. Bilateral nerve grafting (n=9) and bilateral non-nerve sparing (n=10) individuals had similar outcomes (p>0.05). This study lacked randomization and blinding, and subgroup analyses included small numbers of individuals.

A cohort study published by Namiki (2007) included 113 individuals: 19 had unilateral nerve sparing plus sural nerve graft, 60 individuals had unilateral nerve sparing with no grafting, and 34 individuals had bilateral nerve sparing surgery. Function was assessed using validated questionnaires and, at two years, no difference in sexual function scores was found between the unilateral nerve graft and bilateral nerve sparing individuals. At three years, similar percentages of individuals in the unilateral nerve graft (25%) and bilateral nerve sparing (28%) groups considered their sexual function as fair or good. Urinary function returned to baseline continence in the unilateral nerve graft and bilateral nerve sparing groups at six months and in the unilateral nerve sparing group at 12 months. Baseline sexual function differed between groups, which could have biased study findings; the nerve grafted and bilateral nerve sparing individuals reported higher baseline function than the unilateral nerve sparing group.

The remainder of the literature on nerve grafting in association with prostatectomy consists of case series data. While these studies contribute to the body of knowledge by providing direction for future research, evidence from these studies is unreliable due to methodological limitations, such as non-random allocation of treatment and lack of appropriate comparison groups.

PRACTICE GUIDELINE SUMMARY

NATIONAL COMPREHENSIVE CANCER NETWORK

The National Comprehensive Cancer Network (NCCN) prostate cancer guideline (version 3.2022) states that “replacement of resected nerves has not been shown to be beneficial” for recovery of erectile function after radical prostatectomy.

SUMMARY

There is not enough research to show that nerve grafting improves health outcomes for individuals who have undergone radical prostatectomy. No clinical guidelines based on
research recommend nerve grafting for people who have undergone radical prostatectomy. Therefore, this technique is considered not medically necessary.

**REFERENCES**

NOTE: There are no specific CPT codes describing nerve grafting of the cavernous nerves. The CPT codes describing nerve grafts specifically identify the anatomic site and do not include the cavernous nerves. Therefore, CPT code 64999 (unlisted procedure, nervous system) should be used to describe the nerve harvest and grafting component of the procedure. A non-specific CPT code for nerve repair, such as 64910, 64911, 64912, or 64913, may be used.

<table>
<thead>
<tr>
<th>Codes</th>
<th>Number</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>CPT</td>
<td>64999</td>
<td>Unlisted procedure, nervous system</td>
</tr>
<tr>
<td>HCPCS</td>
<td>None</td>
<td></td>
</tr>
</tbody>
</table>

Date of Origin: April 2002